PURPOSE: Circulating cell-free tumor DNA (ctDNA) reflects the heterogeneous spectrum of tumor-specific mutations, especially in systemic disease. We validated plasma-based assays that allow the dynamic quantitative detection of ctDNA as a prognostic biomarker for tumor load and prediction of therapy response in melanoma. MATERIALS AND METHODS: We analyzed plasma-derived ctDNA from a large training cohort (n = 96) of patients with advanced-stage melanoma, with assays for the BRAF V600E and NRAS Q61 driver mutations as well as TERT C250T and TERT C228T promoter mutations. An independent patient cohort (n = 35) was used to validate the utility of ctDNA monitoring under mitogen-activated protein kinase-targeted or immune checkpoint therapies. RESULTS: Elevated plasma ctDNA level at baseline was an independent prognostic factor of disease progression when compared with serum S100 and lactate dehydrogenase levels in multivariable analyses (hazard ratio [HR], 7.43; 95% CI, 1.01 to 55.19; P = .05). The change in ctDNA levels during therapy correlated with treatment response, where increasing ctDNA was predictive for shorter progression-free survival (eg, for BRAF V600E ctDNA, HR, 3.70; 95% CI, 1.86 to 7.34; P < .001). Increasing ctDNA levels predicted disease progression significantly earlier than did routine radiologic scans (P < .05), with a mean lead time of 3.5 months. NRAS-mutant ctDNA was detected in a significant proportion of patients with BRAF-mutant tumors under therapy, but unexpectedly also at baseline. In vitro sensitivity studies suggested that this represents higher-than-expected intratumoral heterogeneity. The detection of NRAS Q61 ctDNA in baseline samples of patients with BRAF V600E mutation who were treated with mitogen-activated protein kinase inhibitors significantly correlated with shorter progression-free survival (HR, 3.18; 95% CI, 1.31 to 7.68; P = .03) and shorter overall survival (HR, 4.08; 95% CI, 1.57 to 10.58; P = .01). CONCLUSION: Our results show the potential role of ctDNA measurement as a sensitive monitoring and prediction tool for the early assessment of disease progression and therapeutic response in patients with metastatic melanoma.
PURPOSE: Circulating cell-free tumor DNA (ctDNA) reflects the heterogeneous spectrum of tumor-specific mutations, especially in systemic disease. We validated plasma-based assays that allow the dynamic quantitative detection of ctDNA as a prognostic biomarker for tumor load and prediction of therapy response in melanoma. MATERIALS AND METHODS: We analyzed plasma-derived ctDNA from a large training cohort (n = 96) of patients with advanced-stage melanoma, with assays for the BRAF V600E and NRAS Q61 driver mutations as well as TERT C250T and TERT C228T promoter mutations. An independent patient cohort (n = 35) was used to validate the utility of ctDNA monitoring under mitogen-activated protein kinase-targeted or immune checkpoint therapies. RESULTS: Elevated plasma ctDNA level at baseline was an independent prognostic factor of disease progression when compared with serum S100 and lactate dehydrogenase levels in multivariable analyses (hazard ratio [HR], 7.43; 95% CI, 1.01 to 55.19; P = .05). The change in ctDNA levels during therapy correlated with treatment response, where increasing ctDNA was predictive for shorter progression-free survival (eg, for BRAF V600E ctDNA, HR, 3.70; 95% CI, 1.86 to 7.34; P < .001). Increasing ctDNA levels predicted disease progression significantly earlier than did routine radiologic scans (P < .05), with a mean lead time of 3.5 months. NRAS-mutant ctDNA was detected in a significant proportion of patients with BRAF-mutant tumors under therapy, but unexpectedly also at baseline. In vitro sensitivity studies suggested that this represents higher-than-expected intratumoral heterogeneity. The detection of NRAS Q61 ctDNA in baseline samples of patients with BRAF V600E mutation who were treated with mitogen-activated protein kinase inhibitors significantly correlated with shorter progression-free survival (HR, 3.18; 95% CI, 1.31 to 7.68; P = .03) and shorter overall survival (HR, 4.08; 95% CI, 1.57 to 10.58; P = .01). CONCLUSION: Our results show the potential role of ctDNA measurement as a sensitive monitoring and prediction tool for the early assessment of disease progression and therapeutic response in patients with metastatic melanoma.
Authors: Liqiang Xi; Trinh Hoc-Tran Pham; Eden C Payabyab; Richard M Sherry; Steven A Rosenberg; Mark Raffeld Journal: Clin Cancer Res Date: 2016-08-01 Impact factor: 12.531
Authors: Ramin Nazarian; Hubing Shi; Qi Wang; Xiangju Kong; Richard C Koya; Hane Lee; Zugen Chen; Mi-Kyung Lee; Narsis Attar; Hooman Sazegar; Thinle Chodon; Stanley F Nelson; Grant McArthur; Jeffrey A Sosman; Antoni Ribas; Roger S Lo Journal: Nature Date: 2010-11-24 Impact factor: 49.962
Authors: Miguel F Sanmamed; Sara Fernández-Landázuri; Carmen Rodríguez; Ruth Zárate; María D Lozano; Leyre Zubiri; José Luis Perez-Gracia; Salvador Martín-Algarra; Alvaro González Journal: Clin Chem Date: 2014-11-19 Impact factor: 8.327
Authors: Hubing Shi; Willy Hugo; Xiangju Kong; Aayoung Hong; Richard C Koya; Gatien Moriceau; Thinle Chodon; Rongqing Guo; Douglas B Johnson; Kimberly B Dahlman; Mark C Kelley; Richard F Kefford; Bartosz Chmielowski; John A Glaspy; Jeffrey A Sosman; Nicolas van Baren; Georgina V Long; Antoni Ribas; Roger S Lo Journal: Cancer Discov Date: 2013-11-21 Impact factor: 39.397
Authors: Gregory A Chang; Jyothirmayee S Tadepalli; Yongzhao Shao; Yilong Zhang; Sarah Weiss; Eric Robinson; Cindy Spittle; Manohar Furtado; Dawne N Shelton; George Karlin-Neumann; Anna Pavlick; Iman Osman; David Polsky Journal: Mol Oncol Date: 2015-09-25 Impact factor: 6.603
Authors: Ademi Santiago-Walker; Robert Gagnon; Jolly Mazumdar; Michelle Casey; Georgina V Long; Dirk Schadendorf; Keith Flaherty; Richard Kefford; Axel Hauschild; Patrick Hwu; Patricia Haney; Anne O'Hagan; Jennifer Carver; Vicki Goodman; Jeffrey Legos; Anne-Marie Martin Journal: Clin Cancer Res Date: 2015-10-07 Impact factor: 12.531
Authors: R J Lee; G Gremel; A Marshall; K A Myers; N Fisher; J A Dunn; N Dhomen; P G Corrie; M R Middleton; P Lorigan; R Marais Journal: Ann Oncol Date: 2018-02-01 Impact factor: 32.976
Authors: Mahrukh M Syeda; Jennifer M Wiggins; Broderick C Corless; Georgina V Long; Keith T Flaherty; Dirk Schadendorf; Paul D Nathan; Caroline Robert; Antoni Ribas; Michael A Davies; Jean Jacques Grob; Eduard Gasal; Matthew Squires; Mahtab Marker; James Garrett; Jan C Brase; David Polsky Journal: Lancet Oncol Date: 2021-02-12 Impact factor: 41.316